SCHEMBL19084549

SCHEMBL19084549

Cc1nn2c(=O)cc(-c3ccc(F)cc3)[nH]c2c1-c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 2/20 0.45
MAPT P10636 3/20 0.41
ARF6 P62330 2/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HTT P42858 1/20 0.40
GCGR P47871 1/20 0.40
MAPK14 Q16539 1/20 0.40
RAB9A P51151 3/20 0.38
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PLAT P00750 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1614418 1.00 PSD (0.45) PSDMAPTARF6MEN1KMT2A
SCHEMBL13515966 0.94 MAPT (0.46) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL17298709 0.90 MEN1 (0.43) MAPTMEN1KMT2AALDH1A1GCGR
SCHEMBL13516328 0.89 TP53 (0.48) MAPTARF6MEN1KMT2AALDH1A1
SCHEMBL13516471 0.89 PLAT (0.43) MAPTALDH1A1GCGRMAPK14RAB9A
SCHEMBL24221653 0.89 PLAT (0.43) MAPTALDH1A1GCGRMAPK14RAB9A
SCHEMBL1613449 0.89 TP53 (0.48) MAPTARF6MEN1KMT2AALDH1A1
SCHEMBL13516457 0.86 GSK3B (0.47) MAPTMEN1KMT2AALDH1A1GCGR
SCHEMBL13516124 0.86 GCGR (0.44) PSDMAPTMEN1KMT2AALDH1A1
SCHEMBL13516217 0.86 GCGR (0.44) PSDMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885MAPT 2995/4885ARF6 1/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885MAPT 2995/4885ARF6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.